Gilead Sciences, Inc. (NASDAQ:GILD) Under Analyst Spotlight

ValuEngine upgraded Gilead Sciences from a buy rating to a strong-buy rating in a research report on Thursday, September 7th. The biopharmaceutical company reported $2.20 earnings per share for the quarter, beating the Zacks' consensus estimate of $2.18 by $0.02. It improved, as 7 investors sold SBA Communications Corporation shares while 4 reduced holdings.

08/29/2017 - Gilead Sciences, Inc. had its "outperform" rating reiterated by analysts at Credit Suisse.

Contrarius Mngmt Limited accumulated 1.07 million shares. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company's stock worth $112,000 after acquiring an additional 144 shares in the last quarter. Moors And Cabot reported 24,983 shares or 0.29% of all its holdings. Moreover, Creative Planning has 0% invested in the company for 300 shares.

Grandfield & Dodd Llc increased its stake in Gilead Sciences Inc (GILD) by 114.16% based on its latest 2017Q2 regulatory filing with the SEC.

About 2,283 shares traded.

Grandfield & Dodd Llc, which manages about $885.55 million and $846.29M US Long portfolio, decreased its stake in Applied Matls Inc (NASDAQ:AMAT) by 38,179 shares to 391,892 shares, valued at $16.19M in 2017Q2, according to the filing. Also, insider John C. Martin sold 73,333 shares of the company's stock in a transaction on Tuesday, August 1st. The Massachusetts-based Schwerin Boyle Capital Management Inc has invested 1.17% in the stock. Tcw Grp Incorporated has 107,444 shares for 0.03% of their portfolio. Bank Of The West who had been investing in Microsoft Corp for a number of months, seems to be bullish on the $587.45 billion market cap company. (NASDAQ:GILD) for 84,699 shares. William Blair reiterated an outperform rating on shares of Gilead Sciences in a research report on Friday, June 16th. Vetr downgraded shares of Gilead Sciences from a "buy" rating to a "hold" rating and set a $86.44 price objective for the a report on Monday, September 4th. Bank of America maintained Gilead Sciences, Inc. Parnassus Investments CA grew its stake in shares of Gilead Sciences by 37.4% in the first quarter. (NASDAQ:GILD) has "Buy" rating given on Thursday, February 25 by Citigroup. The stock has "Hold" rating by Needham on Tuesday, July 26. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. (GILD) Stock Got Its Mojo Back" on September 29, 2017, also with their article: "Why Is Cash-Rich Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by Cogan John Francis. If you are accessing this story on another domain, it was illegally stolen and republished in violation of worldwide trademark & copyright legislation. Bank of New York Mellon Corp grew its stake in shares of Gilead Sciences by 9.8% in the first quarter. August 29 investment analysts at Credit Suisse kept the company rating at "Outperform" but lowered the price expectation to $85.00 from $95.00. Another trade for 5,000 shares valued at $341,529 was made by Alton Gregg H on Monday, May 1. Following the sale, the executive vice president now directly owns 106,113 shares in the company, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. Insiders have sold a total of 486,819 shares of company stock worth $39,298,919 in the last 90 days. The ROE is acquired from a corporation's financial statement and computes the profitability of the investment and how much the company employs its equity. The original version of this story can be viewed at They set a buy rating and a $79.00 price target for the company. The company has market cap of $12.21 billion. The stock was sold at an average price of $75.86, for a total transaction of $5,563,041.38. Equities research analysts expect that Gilead Sciences, Inc. will post $8.75 earnings per share for the current fiscal year. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business's revenue for the quarter was down 8.2% compared to the same quarter a year ago. During the same period previous year, the firm earned $3.08 EPS. Continental Advisors Llc sold 99,300 shares as Gilead Sciences Inc (GILD)'s stock declined 8.05%.

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 29th.

Investors sentiment increased to 0.93 in Q2 2017. However, -3.90% over the last one month, 18.55% for the last quarter and year to date performance stands at 14.70%. The stock's Dividend Yield stands at 2.53%. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Gilead Sciences by 50.0% in the second quarter.

Gilead Sciences, a research biopharmaceutical firm that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome, liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Like this


10 October 2017
Thailand to hold general election in November 2018
Prime Minister Prayuth Chan-ocha told reporters Tuesday that his government will announce the exact election date next year. All politics and protests have been banned under Prayut's regime, the most autocratic Thailand has seen for a generation.

10 October 2017
Giants WR Brandon Marshall To Undergo Ankle Surgery, Out For 2017
A sore finger also limited Beckham after he dislocated it during the Giants Week 4 loss to the Tampa Bay Buccaneers. Fallen giant: Odell Beckham Jr is seen here being taken off the field after a late-game fractured ankle.

10 October 2017
Chhattisgarh govt refuses to reduce Value-Added Tax on fuel despite centre's directive
Andhra Pradesh has 38.82% Value-Added Tax on petrol while BJP- governed Madhya Pradesh levies 38.79% Value-Added Tax on the fuel. Mr Rupani said Gujarat has become the first state to respond to the Centre's appeal to cut taxes on petrol and diesel.

10 October 2017
California governor signs drug pricing transparency law
The pharmaceutical industry is expected to bring a legal challenge to the new regulation before it takes full effect in 2019. The law affects drugs with a wholesale price of more than $40.

10 October 2017
Ronaldo favourite to retain Ballon d'Or
Ligue 1 leaders Paris Saint-Germain also saw their attacking trio of Neymar , Edinson Cavani and Kylian Mbappe among the nominees. It had replaced the FIFA World Player of the year and European footballer of the year award.

10 October 2017
Nokia is killing off its VR unit
Nokia created the Ozo spherical camera to get into the virtual reality market without having to compete with head-mounted devices like the Oculus Rift.

10 October 2017
Details of Jose Mourinho's scouting trip to Austria revealed
Manchester United's manager is interested in Gacinovic, who is comfortable as a central attacking midfielder or on the wing. And now The Mirror reports that the object of Mourinho's affections was in fact Eintracht Frankfurt midfielder Gacinovic.

10 October 2017
A 'new' version of iTunes brings back apps and ringtones
This new-old version of the software should work with any official ringtones you've snagged, audiobooks and iTunes U downloads.

10 October 2017
Android Oreo beta program for Huawei Mate 9 kicks off
And secondly, the beta update is now only available for units running firmware version MHA-L29C432B194. Well, now the Chinese company has started an Android Oreo beta program for the Mate 9.

10 October 2017
Nate's rain arrives tomorrow
Factor in breezy winds and wind gusts up to 30 miles per hour at times, a rather nasty day unfolds across the state. Right now we'll say that system will exit after Thursday leading to fair skies and dry conditions to end the week.